RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia

<h4>Background</h4> A majority of non-invasive prenatal screening studies determining fetal RhD status have been tested on Caucasian and Asian populations, but limited or no studies have been conducted on the Ethiopian population. In the current study, we carried non-invasive prenatal sc...

Full description

Bibliographic Details
Main Authors: Birhanu Niguse, Mihertab Ermias, Solomon Berhanu, Lemma Abayneh, Bekele Chakiso, Riyaz Ahmad Rather
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929601/?tool=EBI
_version_ 1818281315696377856
author Birhanu Niguse
Mihertab Ermias
Solomon Berhanu
Lemma Abayneh
Bekele Chakiso
Riyaz Ahmad Rather
author_facet Birhanu Niguse
Mihertab Ermias
Solomon Berhanu
Lemma Abayneh
Bekele Chakiso
Riyaz Ahmad Rather
author_sort Birhanu Niguse
collection DOAJ
description <h4>Background</h4> A majority of non-invasive prenatal screening studies determining fetal RhD status have been tested on Caucasian and Asian populations, but limited or no studies have been conducted on the Ethiopian population. In the current study, we carried non-invasive prenatal screening of fetal RHD genotype in selected RhD negative Ethiopian pregnant women. <h4>Methods</h4> Cell-free DNA was extracted from the plasma samples of 117 RhD pregnant women between 9 and 38 weeks of gestation. Fetal RHD genotypes were detected by targeting exons 5, 7 and 10 of the RHD gene by using real-time PCR assay. RHD genotypic results were confirmed by neonatal cord blood serology. <h4>Results</h4> Fetal RHD genotyping was conclusive in all 117 subjects. RHD genotype was correctly predicted in 115 of 117 cases, thus the test yielded 98.3% accuracy (95%CI: 97.3–99.1%). Among 115 cases, 105 were genotyped as RHD positive and 12 were genotyped as RHD negative. The sensitivity and specificity of the test were 99.1% (95% CI: 94.8–99.9%) and 91.7% (95%CI: 61.5–99.7%) respectively. The negative and positive predictive values were 99.9% (95%CI: 99.2–99.9%) and 54.0% (95% CI: 15.2–88.4%) respectively. SRY genotyping results were in complete concordance with fetal sex. <h4>Conclusion</h4> Multi exon targeted non-invasive prenatal screening test for fetal RhD determination exhibited high accuracy and sensitivity. A confirmatory study with a bigger size of study subjects is warranted before enabling clinical implementation.
first_indexed 2024-12-13T00:03:10Z
format Article
id doaj.art-571b5708e1524c6887a751e1c0c34d6b
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T00:03:10Z
publishDate 2022-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-571b5708e1524c6887a751e1c0c34d6b2022-12-22T00:06:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01173RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in EthiopiaBirhanu NiguseMihertab ErmiasSolomon BerhanuLemma AbaynehBekele ChakisoRiyaz Ahmad Rather<h4>Background</h4> A majority of non-invasive prenatal screening studies determining fetal RhD status have been tested on Caucasian and Asian populations, but limited or no studies have been conducted on the Ethiopian population. In the current study, we carried non-invasive prenatal screening of fetal RHD genotype in selected RhD negative Ethiopian pregnant women. <h4>Methods</h4> Cell-free DNA was extracted from the plasma samples of 117 RhD pregnant women between 9 and 38 weeks of gestation. Fetal RHD genotypes were detected by targeting exons 5, 7 and 10 of the RHD gene by using real-time PCR assay. RHD genotypic results were confirmed by neonatal cord blood serology. <h4>Results</h4> Fetal RHD genotyping was conclusive in all 117 subjects. RHD genotype was correctly predicted in 115 of 117 cases, thus the test yielded 98.3% accuracy (95%CI: 97.3–99.1%). Among 115 cases, 105 were genotyped as RHD positive and 12 were genotyped as RHD negative. The sensitivity and specificity of the test were 99.1% (95% CI: 94.8–99.9%) and 91.7% (95%CI: 61.5–99.7%) respectively. The negative and positive predictive values were 99.9% (95%CI: 99.2–99.9%) and 54.0% (95% CI: 15.2–88.4%) respectively. SRY genotyping results were in complete concordance with fetal sex. <h4>Conclusion</h4> Multi exon targeted non-invasive prenatal screening test for fetal RhD determination exhibited high accuracy and sensitivity. A confirmatory study with a bigger size of study subjects is warranted before enabling clinical implementation.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929601/?tool=EBI
spellingShingle Birhanu Niguse
Mihertab Ermias
Solomon Berhanu
Lemma Abayneh
Bekele Chakiso
Riyaz Ahmad Rather
RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia
PLoS ONE
title RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia
title_full RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia
title_fullStr RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia
title_full_unstemmed RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia
title_short RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia
title_sort rhd exon 5 7 and 10 targeted non invasive prenatal screening of fetal rhesus d rhd in selected rhd negative pregnant women in ethiopia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929601/?tool=EBI
work_keys_str_mv AT birhanuniguse rhdexon57and10targetednoninvasiveprenatalscreeningoffetalrhesusdrhdinselectedrhdnegativepregnantwomeninethiopia
AT mihertabermias rhdexon57and10targetednoninvasiveprenatalscreeningoffetalrhesusdrhdinselectedrhdnegativepregnantwomeninethiopia
AT solomonberhanu rhdexon57and10targetednoninvasiveprenatalscreeningoffetalrhesusdrhdinselectedrhdnegativepregnantwomeninethiopia
AT lemmaabayneh rhdexon57and10targetednoninvasiveprenatalscreeningoffetalrhesusdrhdinselectedrhdnegativepregnantwomeninethiopia
AT bekelechakiso rhdexon57and10targetednoninvasiveprenatalscreeningoffetalrhesusdrhdinselectedrhdnegativepregnantwomeninethiopia
AT riyazahmadrather rhdexon57and10targetednoninvasiveprenatalscreeningoffetalrhesusdrhdinselectedrhdnegativepregnantwomeninethiopia